ArticleScientific reports2025
Naringin promotes osteoblast differentiation and ameliorates osteoporosis in ovariectomized mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Gut-Bone Axis and Skeletal Health: Regulatory Mechanisms and Therapeutic Applications of Plant-Derived Bioactive Compounds.Biomolecules · 2026Pooled it
- Preclinical effects of naringin on bone outcomes in animal models of osteoporosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- The role of active constituents of in traditional Chinese medicine for primary osteoporosis: a mechanistic review.Frontiers in endocrinology · 2025Pooled it
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
- Arginine Methylation Antagonizes TEAD3-Mediated Repression to Promote Osteogenic Differentiation by Disrupting RUNX2-Sequestrating Condensates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Traditional Chinese Medicine for osteoporosis management: from molecular mechanisms to drug discovery.Chinese medicine · 2026Review
- Naringin Alleviates Knee Osteoarthritis by Targeting TNF-α and PTGS2: An Integrated Network Pharmacology, Molecular Simulation, and Experimental Validation Study.International journal of molecular sciences · 2026Article
- Therapeutic Effects of the Most Common Polyphenols Found inNutrients · 2026Review
- Therapeutic potential of natural products from Traditional Chinese Medicine in the treatment of osteoporosis.Frontiers in pharmacology · 2026Review
- Naringin and denosumab ameliorate osteoporosis and suppress the aldosterone-MR/SGK1 signaling axis by modulating the bone-kidney interorgan communication in Orchiectomized rats.Frontiers in endocrinology · 2026Article
- Naringenin restores osteogenic differentiation in TNF-α-Treated bone marrow mesenchymal stem cells by targeting AKR1B1.Scientific reports · 2025Article
- Resonant acoustic mixing-assisted fabrication and evaluation of FDM-printed PLA/β-TCP scaffolds for bone tissue engineering.Frontiers in bioengineering and biotechnology · 2025Article
- Toward FGF2 reduction in cultured meat media: polyphenol salts enhance growth and differentiation of bESC aggregates.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to investigate the anti-osteoporotic mechanisms of naringin in osteoblasts and mice. In vitro, MC3T3-E1 cells were treated with naringin to detect cell proliferation, alkaline phosphatase (ALP) activity, and calcified nodule formation. Western blot was used to analyze the expression of osteogenic markers (OPN, COL1A1, RUNX2) and Wnt/β-catenin pathway proteins (Wnt3a, β-catenin). In vivo, ovariectomized (OVX) mice were treated with naringin for 3 months to observe bone microstructure, femoral histomorphology, and marker expression. Results showed that 0.1, 0.5, and 1 µmol/L naringin significantly promoted cell proliferation, enhanced ALP activity, and increased calcified nodule formation. Naringin also improved bone mineral density (BMD) and trabecular bone number in OVX mice. It elevated serum levels of bone formation markers (P1NP, OCN) while reducing the bone resorption marker CTX-1. Both in vitro and in vivo, naringin upregulated OPN, COL1A1, RUNX2, Wnt3a, and β-catenin expression, and induced β-catenin nuclear translocation. Notably, naringin antagonized the inhibitory effects of XAV939 (a Wnt/β-catenin pathway inhibitor) on OPN, COL1A1, and RUNX2 protein expression. These findings demonstrate that naringin enhances bone density in OVX mice and promotes osteogenic differentiation of MC3T3-E1 cells via activation of the Wnt/β-catenin pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.